{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:25:17Z","timestamp":1772753117116,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.ygyno.2012.02.034","type":"journal-article","created":{"date-parts":[[2012,2,28]],"date-time":"2012-02-28T13:34:02Z","timestamp":1330436042000},"page":"640-645","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube"],"prefix":"10.1016","volume":"125","author":[{"given":"Ignacio Romero","family":"Noguera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte C.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell R.","family":"Broaddus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Branham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles F.","family":"Levenback","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro T.","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Gershenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ygyno.2012.02.034_bb0005","first-page":"69","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2012.02.034_bb0010","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading ovarian serous carcinomas using a two-tier system","volume":"28","author":"Malpica","year":"2004","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.ygyno.2012.02.034_bb0015","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ygyno.2006.05.030","article-title":"Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum","volume":"103","author":"Seidman","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ygyno.2012.02.034_bb0020","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11912-008-0078-8","article-title":"Low-grade serous ovarian cancer: a unique disease","volume":"10","author":"Schmeler","year":"2008","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"10.1016\/j.ygyno.2012.02.034_bb0025","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/01.AOG.0000227787.24587.d1","article-title":"Clinical behavior of stage II\u2013IV low-grade serous carcinoma of the ovary","volume":"108","author":"Gershenson","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.ygyno.2012.02.034_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ygyno.2012.02.034_bb0035","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2012.02.034_bb0040","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2009.03.001","article-title":"Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant","volume":"114","author":"Gershenson","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ygyno.2012.02.034_bb0045","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/IGC.0b013e31821b2568","article-title":"2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference","volume":"21","author":"Stuart","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2012.02.034_bb0050","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR\u2013ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2012.02.034_bb0055","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr\u2013Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"issue":"14","key":"10.1016\/j.ygyno.2012.02.034_bb0060","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1056\/NEJM200104053441404","article-title":"Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor","volume":"344","author":"Joensuu","year":"2001","journal-title":"N Engl J Med"},{"issue":"9440","key":"10.1016\/j.ygyno.2012.02.034_bb0065","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","article-title":"Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial","volume":"364","author":"Verweij","year":"2004","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ygyno.2012.02.034_bb0070","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","article-title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033","volume":"26","author":"Blanke","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ygyno.2012.02.034_bb0075","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1200\/JCO.2009.25.7899","article-title":"Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials","volume":"28","author":"Rutkowski","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ygyno.2012.02.034_bb0080","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.leukres.2011.05.006","article-title":"Tyrosine kinase inhibitors in the treatment of systemic mastocytosis","volume":"35","author":"Ustun","year":"2011","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.ygyno.2012.02.034_bb0085","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.pai.0000173054.83414.22","article-title":"KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation","volume":"13","author":"Miettinen","year":"2005","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"12","key":"10.1016\/j.ygyno.2012.02.034_bb0090","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1038\/sj.bjc.6602252","article-title":"Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma","volume":"91","author":"Lassus","year":"2004","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2012.02.034_bb0095","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/cncr.11561","article-title":"Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium","volume":"98","author":"Schmandt","year":"2003","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2012.02.034_bb0100","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1158\/1078-0432.CCR-1151-3","article-title":"Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma","volume":"10","author":"Apte","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ygyno.2012.02.034_bb0105","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s00432-008-0408-0","article-title":"Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects","volume":"134","author":"Mundhenke","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2012.02.034_bb0110","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ygyno.2006.10.052","article-title":"AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate","volume":"105","author":"Shaw","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2012.02.034_bb0115","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ygyno.2005.09.041","article-title":"Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers","volume":"101","author":"Coleman","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.02.034_bb0120","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ygyno.2012.02.034_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"issue":"282","key":"10.1016\/j.ygyno.2012.02.034_bb0130","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"6","key":"10.1016\/j.ygyno.2012.02.034_bb0135","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1158\/1078-0432.CCR-09-3287","article-title":"The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the National Cancer Institute Investigational Drug Steering Committee","volume":"16","author":"Seymour","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.ygyno.2012.02.034_bb0140","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/jnci\/95.13.1009-a","article-title":"KIT in ovarian carcinoma: disillusion about a potential therapeutic target","volume":"95","author":"Singer","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ygyno.2012.02.034_bb0145","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3346\/jkms.2006.21.1.81","article-title":"Expression and mutational analysis of c-kit in ovarian surface epithelial tumors","volume":"21","author":"Kim","year":"2006","journal-title":"J Korean Med Sci"},{"issue":"3","key":"10.1016\/j.ygyno.2012.02.034_bb0150","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.humpath.2004.11.009","article-title":"Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers","volume":"36","author":"Wilczynski","year":"2005","journal-title":"Hum Pathol"},{"issue":"5","key":"10.1016\/j.ygyno.2012.02.034_bb0155","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0046-8177(98)90066-1","article-title":"Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders","volume":"29","author":"Arber","year":"1998","journal-title":"Hum Pathol"},{"issue":"19","key":"10.1016\/j.ygyno.2012.02.034_bb0160","first-page":"5476","article-title":"Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy","volume":"62","author":"Pietras","year":"2002","journal-title":"Cancer Res"},{"issue":"17","key":"10.1016\/j.ygyno.2012.02.034_bb0165","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.1158\/0008-5472.CAN-04-3991","article-title":"Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy","volume":"65","author":"Baranowska-Kortylewicz","year":"2005","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.ygyno.2012.02.034_bb0170","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.4161\/cbt.6.12.4976","article-title":"PDGF BB induces VEGF secretion in ovarian cancer","volume":"6","author":"Matei","year":"2007","journal-title":"Cancer Biol Ther"},{"issue":"11","key":"10.1016\/j.ygyno.2012.02.034_bb0175","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"33","key":"10.1016\/j.ygyno.2012.02.034_bb0180","doi-asserted-by":"crossref","first-page":"5360","DOI":"10.1200\/JCO.2008.17.4284","volume":"26","author":"Heinrich","year":"2008","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ygyno.2012.02.034_bb0185","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.ejca.2006.01.030","article-title":"KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours","volume":"42","author":"Debiec-Rychter","year":"2006","journal-title":"Eur J Cancer"},{"issue":"9574","key":"10.1016\/j.ygyno.2012.02.034_bb0190","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/S0140-6736(07)60780-6","article-title":"Gastrointestinal stromal tumour","volume":"369","author":"Rubin","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2012.02.034_bb0195","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1200\/JCO.2007.14.3420","article-title":"Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma. A Gynecologic Oncology Group Study","volume":"26","author":"Schilder","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2012.02.034_bb0200","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/cncr.22757","article-title":"A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling","volume":"110","author":"Posadas","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2012.02.034_bb0205","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1136\/ijgc-00009577-200707000-00005","article-title":"Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211)","volume":"17","author":"Alberts","year":"2007","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2012.02.034_bb0210","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/cncr.23605","article-title":"Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial","volume":"113","author":"Matei","year":"2008","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.ygyno.2012.02.034_bb0215","first-page":"3243","article-title":"Weekly paclitaxel with intermittent imatinib mesylate (Gleevec): tolerance and activity in recurrent epithelial ovarian cancer","volume":"30","author":"Safra","year":"2010","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.ygyno.2012.02.034_bb0220","first-page":"568","article-title":"A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission","volume":"29","author":"Juretzka","year":"2008","journal-title":"Eur J Gynaecol Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ygyno.2012.02.034_bb0225","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1007\/s00280-010-1527-2","article-title":"The role of imatinib plasma level testing in gastrointestinal stromal tumor","volume":"67","author":"George","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.ygyno.2012.02.034_bb0230","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ctrv.2010.10.001","article-title":"Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?","volume":"37","author":"von Mehren","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ygyno.2012.02.034_bb0235","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1101\/gad.1653708","article-title":"Role of platelet-derived growth factors in physiology and medicine","volume":"22","author":"Andrae","year":"2008","journal-title":"Genes Dev"},{"issue":"3","key":"10.1016\/j.ygyno.2012.02.034_bb0240","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4161\/cbt.9.3.10635","article-title":"Targeting pericytes with a PDGF-\u0392 aptamer in human ovarian carcinoma models","volume":"9","author":"Lu","year":"2010","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"10.1016\/j.ygyno.2012.02.034_bb0245","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4161\/mabs.2.1.10498","article-title":"A dual-targeting PDGFR-\u0392\/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo","volume":"2","author":"Mabry","year":"2010","journal-title":"MAbs"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825812001606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825812001606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:28:47Z","timestamp":1758770927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825812001606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0090825812001606"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2012.02.034","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2012.02.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}